Press Releases 2014


 
2014 | 2013 | 2012 | 2011
DateTitle 
December 09, 2014Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis... 
Printer Friendly Version
December 04, 2014FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
The first and only FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack1 Jakafi is the only treatment for patients with PV shown to provide consistent hematocrit con... 
Printer Friendly Version
December 02, 2014Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
New analyses of the RESPONSE trial provide additional insights into the efficacy of ruxolitinib in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea Data from the COMFORT, JUMP, and EXPAND trials reinforce the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF) Data from trials of the combination of ruxolitinib and other targeted agen... 
Printer Friendly Version
November 17, 2014Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 17, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of December: Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:00 pm (EST) in New York; and Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014 at 10:20 am (EST) in New York ... 
Printer Friendly Version
October 30, 2014Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$97.8 million of 2014 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 63 percent growth over the same period last year 2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand Two milestone payments from Novartis earned in the third quarter, totaling $85 million ... 
Printer Friendly Version
October 23, 2014Incyte to Present at the Nomura BioPharma Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 23, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Nomura BioPharma Conference on Thursday, November 6, 2014 at 1:15 p.m. (EST) in Boston. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the live webcast should ... 
Printer Friendly Version
October 17, 2014Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 17, 2014-- Incyte Corporation (NASDAQ: INCY) today announced the appointment of David Gryska as Executive Vice President and Chief Financial Officer, effective October 31, 2014. Mr. Gryska will report to Hervé Hoppenot, President and Chief Executive Officer. Mr. Gryska will succeed David Hastings, who has served as Incyte’s Executive Vice President and Chief Financial Officer since October 2003. Mr. ... 
Printer Friendly Version
October 15, 2014Incyte to Report Third Quarter 2014 Financial Results on October 30
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 15, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, October 30, 2014. The schedule for the press release and conference call is as follows:           ... 
Printer Friendly Version
October 02, 2014Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxolitinib) in Europe
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 2, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has earned a $60 million milestone payment from Novartis related to reimbursement of Jakavi® (ruxolitinib) in Europe. Incyte will record this amount as contract revenue in the third quarter, and expects to receive payment of $60 million in the fourth quarter. Under the Incyte-Novartis Collaboration and License Agreement signed in 200... 
Printer Friendly Version
September 08, 2014Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called Myeloproliferative Neoplasms (MPNs) and Honor MPN Heroes
Initiatives focus on increasing MPN Awareness Multiple patient education events scheduled throughout September Call for nominations – MPN Heroes™ recognition program WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2014-- September is Blood Cancer Awareness Month, and the MPN Coalition, a group of seven patient organizations, has designated September 11, 2014, as MPN Awareness Day. This day recognizes the approxi... 
Printer Friendly Version
September 08, 2014Incyte to Present at the 21st Annual BioCentury NewsMakers Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26, 2014 at 2:00 p.m. (EDT) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the li... 
Printer Friendly Version
August 05, 2014FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 5, 2014-- Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The sNDA includes results from the RESPONSE Phase III trial, which were recently presen... 
Printer Friendly Version
July 31, 2014Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$84.0 million of 2014 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 55 percent growth over the same period last year 2014 guidance for Jakafi net product revenues increased to range of $330 million to $340 million, driven by strong underlying demand Timely initiation of key pipeline programs, including initiation of two pivotal trials of ruxolitinib in pancreatic cancer and three ... 
Printer Friendly Version
July 30, 2014Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies
Incyte’s investigational oral IDO1 inhibitor INCB24360 to be evaluated with Genentech’s investigational PD-L1 immune checkpoint inhibitor MPDL3280A WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 30, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibit... 
Printer Friendly Version
July 28, 2014Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information
Jakafi is the first and only FDA-approved treatment for patients with intermediate or high-risk myelofibrosis WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 28, 2014-- Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food & Drug Administration (FDA) has approved supplemental labeling for Jakafi® (ruxolitinib) to include new Kaplan-Meier overall survival curves as well as additional safety and dosing information. The new overall surv... 
Printer Friendly Version
July 23, 2014Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera
Statistical significance not achieved for the primary endpoint of symptom control; positive trends in favor of ruxolitinib versus hydroxyurea observed RELIEF trial conducted in patients who were generally well-controlled on hydroxyurea but reporting continued disease-related symptoms, a different population than the pivotal Phase III RESPONSE trial RELIEF not included in, nor required for, polycythemia... 
Printer Friendly Version
July 14, 2014Incyte to Report Second Quarter 2014 Financial Results on July 31
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, July 31, 2014. The schedule for the press release and conference call is as follows: Q2 2014 Press Release: July 31, 2014 at 7:00 a.m. ET Q2 2014 Conference Call: July 31, 2014 at 8:30 a.m. ET ... 
Printer Friendly Version
July 08, 2014Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 8, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract revenue in the third quarter. Under the Incyte-Novartis Collaboration and License Agreement, Novartis received exclusive develo... 
Printer Friendly Version
June 12, 2014Incyte to Present at the 9th Annual JMP Securities Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 12, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 11:00 a.m. (EDT) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the ... 
Printer Friendly Version
June 03, 2014Pivotal Phase III Data in Polycythemia Vera Show that Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies
The trial met the primary composite endpoint of hematocrit control and at least a 35 percent reduction in spleen volume 77 percent of patients treated with ruxolitinib versus 20 percent on best available therapy achieved one or both of the components of the primary endpoint Approximately half of patients in the ruxolitinib group had at least a 50 percent improvement in symptom score, compared with 5 pe... 
Printer Friendly Version
June 02, 2014Incyte Announces Preliminary Results of a Phase I/II Study of Combination Immunotherapy in Patients with Melanoma
Clinical data suggest anti-tumor synergy between Incyte’s IDO1 inhibitor INCB24360 and ipilimumab described in an ASCO poster highlights session Among immunotherapy-naïve patients receiving INCB24360 combined with ipilimumab, 42 percent had an objective response and 75 percent achieved disease control IDO1 inhibitor-based combination therapy represents a promising and potentially synergistic approach t... 
Printer Friendly Version
June 02, 2014Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi® (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer
Overall survival favored ruxolitinib plus capecitabine versus capecitabine alone in pre-specified subgroup of patients with elevated CRP, an established marker of systemic inflammation and poor prognosis in cancer These data support targeting onco-inflammation through the JAK-STAT pathway and form the basis of an expanded clinical development program evaluating ruxolitinib in pancreatic cancer and other solid tumor types ... 
Printer Friendly Version
May 28, 2014New Data for Multiple Incyte Cancer Programs to Be Presented at the 2014 American Society of Clinical Oncology (ASCO) Meeting
Results from RECAP, a Phase II trial of ruxolitinib in metastatic pancreatic cancer and proof-of-concept for the role of a JAK1/JAK2 inhibitor in treating onco-inflammation Preliminary results from an ongoing Phase I/II trial of INCB24360, a novel immuno-oncology compound, in combination with ipilimumab in metastatic melanoma Results from RESPONSE, a pivotal Phase III trial of ruxolitinib in uncontroll... 
Printer Friendly Version
May 27, 2014Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Phase I/II study to evaluate nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor with Incyte’s investigational oral IDO1 inhibitor for multiple cancers NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)--May 27, 2014-- Bristol-Myers Squibb Company (NYSE: BMY) and Incyte Corporation (Nasdaq: INCY) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and prel... 
Printer Friendly Version
May 20, 2014Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May 20, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of June: Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 10:30 am (EDT) in New York; Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, 2014 at 10:40 am (PDT) / 1:40 pm (EDT) in Rancho Palo... 
Printer Friendly Version
May 14, 2014Incyte and MedImmune Announce Collaboration on Immuno-Oncology Combination Clinical Trial
WILMINGTON, Del.--(BUSINESS WIRE)--May 14, 2014-- Incyte Corporation (Nasdaq: INCY) and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into a clinical study collaboration. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) ... 
Printer Friendly Version
May 02, 2014Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May 2, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch Health Care Conference on Tuesday, May 13, 2014 at 11:20 am (PDT) in Las Vegas; and UBS Global Healthcare Conference on Monday, May 19, 2014 at 10:30 am (EDT) in New York The presentations... 
Printer Friendly Version
May 01, 2014Incyte Reports 2014 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$69.7 million of 2014 first-quarter net product revenues from Jakafi® (ruxolitinib); 6 percent increase in underlying demand over fourth-quarter 2013 Positive top-line results from Phase III study of ruxolitinib in patients with polycythemia vera keep sNDA filing on track for second quarter 2014 Abstracts for ruxolitinib in pancreatic cancer and polycythemia vera and for IDO1 inhibitor INCB24360 in mel... 
Printer Friendly Version
April 16, 2014Incyte to Report First Quarter 2014 Financial Results on May 1
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 16, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, May 1, 2014. The schedules for the press release and conference call are as follows:         ... 
Printer Friendly Version
March 07, 2014Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Study of ruxolitinib versus best available therapy for patients with polycythemia vera who are resistant to or intolerant of hydroxyurea met primary endpoint Ruxolitinib is the first selective JAK1/JAK2 inhibitor to demonstrate efficacy in a Phase III trial for treating polycythemia vera Data expected to be presented at an upcoming scientific meeting Supplemental new drug application pl... 
Printer Friendly Version
February 18, 2014Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 18, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March: Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 2:10 pm (EST) in Boston; and Barclays Capital Global Healthcare Conference on Tuesday, March 11, 2014 at 11:15 am (EST) in Miami The ... 
Printer Friendly Version
February 12, 2014Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs
$72.9 million of fourth-quarter and $235.4 million of full-year 2013 net product revenues from Jakafi® (ruxolitinib) Net product revenue guidance for 2014 in the range of $315 million to $335 million, reflecting continued growth in underlying demand Special Protocol Assessment obtained for Phase III clinical trial of ruxolitinib in advanced or metastatic pancreatic cancer Conference Call Scheduled... 
Printer Friendly Version
February 05, 2014Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies
Phase I/II study to evaluate the safety and efficacy of Incyte’s investigational oral IDO1 inhibitor with Merck’s investigational anti-PD-1 immunotherapy for metastatic cancers WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 5, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte’s oral indoleamine... 
Printer Friendly Version
January 27, 2014Incyte to Report Fourth Quarter/Year-End 2013 Financial Results on February 12
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter/year-end 2013 financial results conference call for 8:30 a.m. ET on Wednesday, February 12, 2014. The schedules for the press release and conference call are as follows:       ... 
Printer Friendly Version
January 14, 2014Incyte Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 14, 2014-- Incyte Corporation (Nasdaq: INCY) today announced that in connection with the hiring, announced on January 13, 2014, of Hervé Hoppenot as President and Chief Executive Officer, Mr. Hoppenot received an award of restricted stock units (RSUs) to acquire 400,000 shares of Incyte common stock. The RSUs will vest in equal annual increments over a six year period, with the first installment vesting on December... 
Printer Friendly Version
January 13, 2014Incyte Names Hervé Hoppenot President and Chief Executive Officer
Former President of Novartis Oncology to Lead Incyte’s Future Growth WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 13, 2014-- Incyte Corporation (Nasdaq:INCY) announced today that Hervé Hoppenot, former President of Novartis Oncology, has been named President and Chief Executive Officer of Incyte, effective immediately. Mr. Hoppenot, who also will join the Incyte Board of Directors, succeeds Paul A. Friedman, M.D. Dr. Friedman is retiring and will continue to serve on the Board. “Hervé’s broad int... 
Printer Friendly Version